Eli Lilly and Company logo
Eli Lilly and Company (LLY)
Compare

Eli Lilly and Company (LLY) SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

FormFiling DateAcceptedDocument
25-NSEJun 2, 2026Jun 2, 2026View filing
8-KMay 20, 2026May 20, 2026View filing
4May 19, 2026May 19, 2026View filing
4May 19, 2026May 19, 2026View filing
4May 19, 2026May 19, 2026View filing
4May 19, 2026May 19, 2026View filing
SDMay 11, 2026May 11, 2026View filing
424B2May 8, 2026May 8, 2026View filing
8-KMay 7, 2026May 7, 2026View filing
4May 7, 2026May 7, 2026View filing
FWPMay 6, 2026May 6, 2026View filing
424B2May 6, 2026May 6, 2026View filing
10-QApr 30, 2026Apr 30, 2026View filing
8-KApr 30, 2026Apr 30, 2026View filing
PX14A6GApr 29, 2026Apr 29, 2026View filing
4Apr 21, 2026Apr 21, 2026View filing
4Apr 21, 2026Apr 21, 2026View filing
4Apr 21, 2026Apr 21, 2026View filing
4Apr 21, 2026Apr 21, 2026View filing
SC 13G/AApr 20, 2026Apr 20, 2026View filing
DFAN14AMar 31, 2026Mar 31, 2026View filing
SC 13G/AMar 26, 2026Mar 26, 2026View filing
DEFA14AMar 20, 2026Mar 20, 2026View filing
DEF 14AMar 20, 2026Mar 20, 2026View filing
4Mar 17, 2026Mar 17, 2026View filing
4Mar 17, 2026Mar 17, 2026View filing
4Mar 17, 2026Mar 17, 2026View filing
4Mar 17, 2026Mar 17, 2026View filing
PRE 14AMar 6, 2026Mar 6, 2026View filing
4Feb 19, 2026Feb 19, 2026View filing

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN
47,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks